Contents lists available at ScienceDirect





journal homepage: www.elsevier.com/locate/ijcard

International Journal of Cardiology

Maintenance of sinus rhythm after electrical cardioversion for recurrent atrial fibrillation following mitral valve surgery with or without associated radiofrequency ablation



Henrica N.A.M. van Breugel^{a,1}, Sandro Gelsomino^{a,b,*,1}, Cees B. de Vos^a, Ryan E. Accord^a, Robert G. Tieleman^a, Fabiana Lucà^b, Carlo Rostagno^b, Attilio Renzulli^c, Orlando Parise^{a,c}, Roberto Lorusso^c, Harry J.G.M. Crijns^a, Jos G. Maessen^a

^a University Hospital, Maastricht, The Netherlands

^b Careggi Hospital, Florence Italy

^c University of Magna Graecia, Catanzaro, Italy

ARTICLE INFO

Article history: Received 25 September 2013 Received in revised form 30 March 2014 Accepted 11 May 2014 Available online 16 May 2014

Keywords: Atrial fibrillation Electrical cardioversion Ablation surgery

ABSTRACT

Background: This study reports the outcomes of patients who underwent electrical cardioversion for atrial fibrillation recurrence following mitral valve surgery and associated radiofrequency ablation compared to those who did not undergo concomitant atrial fibrillation ablation.

Methods: The population consisted of 116 patients with persistent/long-standing persistent AF who underwent mitral valve surgery with (Group A, n = 54) or without (Group B, n = 62) associated radiofrequency ablation between January 2007 and January 2011 at three institutions and who subsequently underwent cardioversion for persistent atrial fibrillation within 12 months of their initial procedure.

Results: The mean follow-up duration was 30.7 ± 9.4 months. Of the 104 patients with acute restoration of SR 42 (40.3%) had AF recurrence. The average time to recurrence after cardioversion was 7.3 ± 4.2 days. Recurrence was significantly lower in patients undergoing ablation surgery (21.4%) than in those undergoing no ablation surgery (78.6%, p < 0.001). Non-performed ablation procedure (p < 0.001), time from surgery ≥ 88 days and left atrial dimensions ≥ 45.5 mm before cardioversion (both, p = 0.005) were multivariable predictors of atrial fibrillation recurrence. In Group B the use of amiodarone was inversely correlated with recurrence of AF (p < 0.001). This correlation was not significant (r = -0.02, p = 0.85) in Group A.

Conclusions: Electrical cardioversion for recurrent AF showed better results and stable recovery of sinus rhythm in patients undergoing concomitant surgical ablation during mitral valve surgery. This might be attributable to substrate modification caused by surgical lesions. Amiodarone improved the ECV-success rate only in patients with no associate ablation. Further larger randomized studies are necessary to confirm our findings.

© 2014 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Since its introduction in 1989 by Cox and colleagues [1], the surgical treatment of atrial fibrillation (AF) has experienced a new dawn during the past few years [2]. Technological innovations have helped to simplify the original Maze technique replacing the surgical incisions with transmural ablation lines created by various energy sources [3].

In patients with mitral valve disease preoperative AF is present in 30–50% and it is associated with less favorable short- and long-term

¹ The first two authors equally contributed to the paper.

outcomes. It has been demonstrated that surgical correction of the underlying cardiac abnormality usually will not abolish AF that has been present for 6 months or more [4,5]. In contrast, the Maze procedure associated to mitral valve surgery is reported to have several clinical benefits [6–8] and to restore stable sinus rhythm with a success rate ranging from 74% to 83% [9,10].

Electrical cardioversion (ECV) is commonly recommended for patients with recurrent AF following an initial ablation procedure. Nonetheless, although the long-term effect of ECV might be promising under these circumstances, it has been reported that >80% of patients who undergo ECV for persistent AF or atrial flutter after catheter ablation have recurrence [11] and little is known about the benefit of ECV, with or without additional pharmacological pre-treatment, after unsuccessful ablation surgery.

Therefore, the purpose of this study is to report early and mid-term outcomes of patients who underwent ECV for AF recurrence following

Abbreviations: ECV, electrical cardioversion; AF, atrial fibrillation.

^{*} Corresponding author at: Dept. of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht – CARIM, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Tel.: + 31 43 388 1067; fax: + 31 43 387 77070.

E-mail address: sandro.gelsomino@maastrichtuniversity.nl (S. Gelsomino).

mitral valve surgery and associated radiofrequency (RF) ablation compared to those who did not undergo concomitant AF ablation. We also examined multiple pre-procedural and peri-procedural variables to determine predictors of AF recurrence after cardioversion.

2. Methods

2.1. Patient population

Ethical Committee approval was waived due to the retrospective analysis of the study according to National laws regulating observational retrospective studies (Italian law nr. 11960, released on 13/07/2004; Dutch law). However, written informed consent was obtained from all the patients prior to the surgical procedure.

The patient population consisted of 116 patients with persistent and long-standing persistent AF who survived mitral valve surgery with (Group A, n = 54) or without (Group B, n = 62) associated radiofrequency AF ablation between January 2007 and January 2011 at three institutions (Careggi Hospital, Florence, Italy; University Hospital, Catanzaro, Italy; University Hospital, Maastricht, the Netherlands) and who subsequently

Table 1

Baseline characteristics and surgical data (n = 116).

underwent ECV for persistent AF within 12 months of their initial procedure. During this interval a total of 317 patients with mitral disease and AF underwent cardiac surgery at these institutions and, among them, 115 (36.2%) had concomitant ablation surgery.

Sixteen patients refused ECV or did not undergo cardioversion because of contraindication. Patients with paroxysmal AF, those who underwent prior cardiac surgery or catheter ablation and those with postoperative residual/recurrent moderate mitral or tricuspid regurgitation were excluded from this study. Atrial fibrillation was defined according to the Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society [12]. Clinical characteristics are shown in Table 1. Baseline data were comparable in the two Groups.

2.2. Surgical technique

Indication to surgical ablation was given following the recent European Society of Cardiology Guidelines [13]. However, the final decision to perform or not perform a surgical ablation was at the attending surgeon's discretion. All operations were carried out on cardiopulmonary bypass with cardiac arrest being achieved with antegrade blood cardioplegia. The mitral valve surgery was performed through a standard left atriotomy and different techniques of mitral repair were accomplished according to the underlying

Group A Group A Group B p Aladio group (n = 62) (n = 62) Age 699 ± 8.6 68.2 ± 8.9 NS Ser (male/fenale) 28/26 (51.8/82.2) 31/31 (50.50) NS Body mass index (lg/m²) 26.0 ± 3.1 26.7 ± 2.8 NS Co-morbidities 14 (25.9) 15 (24.1) NS Corboroid dives (lg/m²) 26.0 ± 3.1 6 (36.1) NS Corborid dives (lg/m²) 26.0 ± 3.1 6 (36.1) NS Corborizacitar dives (lg/m²) 26.0 ± 3.1 2 (32.1) NS Corborizacitar dives (lg/m²) 16 (25.1) 15 (24.1) NS Corborizacitar dives (lg/m²) 2 (37.1) 3 (48.1) NS Conside dives (lg/m²) 13 (25.5) 5 (80.1) NS Conside dives (lg/m²) 2 (32.1) NS NS Conside dives (lg/m²) 2 (20.2) 2 (21.2) NS Arial fibrillation (lg/m²) 2 (20.2) 2 (21.3) NS Arial fibrillation (lg/m²) 2 (20.2) 2 (21.3)
Ablation group No ablation group $(n = 54)$ $(n = 62)$ Age 699 ± 8.6 682 ± 8.9 NS Sox (male/formale) 26.0 ± 3.1 26.7 ± 2.8 NS Doby mass index (lg/m ²) 26.0 ± 3.1 26.7 ± 2.8 NS Co-morbidities $21(32,0)$ NS Diabets $14(25.9)$ $15(24.1)$ NS Diabets $6(11.1)$ $6(36.5)$ NS Co-morbidities NS Cornorit obstructive pulmonary disease $6(11.1)$ $6(36.1)$ NS Congestive heart failure $3(55.5)$ $5(80.0)$ NS Renal failure $22(40.7)$ $26(41.9)$ NS Arrial fibrillation type $22(40.7)$ $26(41.9)$ NS II $30(55.6)$ $27(43.6)$ NS II $30(54.0, -22.1)$ $6(51.0, -27.0)$ NS New York Heart Association before surgery (months) $33(27.44)$ $28(21.37)$ NS New York Heart Sociation Functional Class $12(22.2)$ $27(43.6)$ $27(43.6)$ <t< th=""></t<>
(n = 54) $(n = 62)$ Age699 ± 8.668.2 ± 8.9NSSex (male/female)28/26 (51.8/46.2)31/31 (50.50)NSBody mass index (lg/m²)26.0 ± 3.126.7 ± 2.8NSCo-motividites20 (37.1)21 (33.9)NSPhyternsion20 (37.1)6 (9.6)NSCo-motividites14 (25.9)15 (24.1)NSCorborovascular disease6 (11.1)6 (9.6)NSCorborovascular disease6 (11.1)6 (9.6)NSCorborovascular disease3 (5.5)5 (8.0)NSConsci extreme2 (32.2)NSArrial fibrillation type2 (32.2)NSPersistent32 (59.3)36 (58.1)NSLong-standing persistent22 (40.7)26 (41.9)NSNew York Heart Association Functional Class3 [2-3-1]3 [2-3]NSIl12 (22.2)21 (33.9)NSNSIl30 (55.6)27 (43.6)NSIl30 (55.6)27 (43.6)NSIl30 (55.6)27 (43.6)NSIl31 (40-6.2]6.0 (50-7.0)NSMitral valve pathology11 (19.1)11 (17.7)NSPegenerative26 (48.2)31 (50.1)NSInscince12 (22.2)14 (22.5)NSInscince14 (25.9)14 (22.5)NSIndication14 (25.9)14 (22.5)NSIndication14 (25.9)14 (22.5)NSIndication14 (25.9)
Age699±8.6822±9.9NSSe (male/mar)28/26 (51.8/42.)31/31 (50.50)NSBody mass index (lg/m²)20.60±3.126.7±2.8NSCo-motildites20 (37.1)1 (39.0)NSPhaters20 (37.1)21 (33.0)NSDiabetes14 (25.9)1 (24.1)NSConcis obstructive pulmonary disease(11.1)6 (9.6)NSConcis obstructive pulmonary disease3 (5.5)5 (8.0)NSRenal failure3 (5.5)5 (8.0)NSRenal failure20 (37.4)26 (41.9)NSArtial fibrillation type26 (41.9)NSIt if birillation duration before surgery (months)33 (27-44]28 (21-37]NSNew York Heart Association Functional Class3 (22.3)21 (33.9)NSIt12 (22.2)14 (22.5)NSIt10 (55.6)11 (17.7)NSNew York Heart Association Functional Class33 (40-62.1)60 (50.7)NSNew York Heart Association Functional4 (25.9)14 (22.5)NSIt11 (37.1)NSNSNSDegenerative2 (64.2)1 (51.1)NSIterational4 (25.9)14 (25.9)NSDegenerative2 (64.2)1 (51.1)NSInstructure11 (39.1)11 (37.1)NSNot details11 (39.1)11 (37.1)NSNot details11 (39.1)11 (39.1)NSIte attails (Structure11 (39.1)11 (39.1)<
SerAppleAppleAppleAppleAppleAppleNsBody mass index (kg/m²)26.0 ± 3.126.7 ± 2.8NsCo-morbidities20.7121.33.9NsDiabetes14 (25.915 (24.1)NsCorreor oxacular disease6 (11.1)6 (9.6)NsCorreor oxacular disease6 (11.1)6 (9.6)NsCorreor oxacular disease15 (25.3)3 (4.8)NsConsci ostructive pulmonary disease3 (5.5)5 (8.0)NsConsci ostructive pulmonary disease22 (90.7)2 (32.7)NsRenal failure21 (29.3)3 (5 (4.1)NsConsci ostructive pulmonary disease3 (25.7)3 (6 (4.1)NsArrial fibrillation type22 (40.7)26 (41.9)NsPersistent22 (40.7)28 [21-37]NsNew York Heart Association Functional Class3 [27-4]3 [2.3]NsNew York Heart Association Functional Class3 [2.4]3 [2.4]NsNew York Heart Association Functional Class3 [2.4]3 [2.3]NsNew York Heart Association Functional Class3 [2.4]11 (17.7)NsNew York Heart Association Functional Class3 [4.0-62]10 (50.7.0]NsIl10 (22.2)11 (31.0)11 (31.0)11 (31.0)11 (31.0)New York Heart Association Functional2 (40.7)4 (42.5)11 (41.0)11 (41.0)New York Heart Association Functional Class3 [4.0-62]10 (50.6)11 (50.1)11 (50.1)
bdy mass index (kg/m²) 260 ± 3.1 267 ± 2.8 NS Co-motbilities 7 2.03 ± 3.1 2.03 ± 2.8 NS Co-motbilities 7 2.03 ± 3.1 2.03 ± 3.1 NS Diabetes 2.03 ± 3.1 2.03 ± 3.1 NS NS Diabetes 1.4 (25.9) 15 (24.1) NS Corborix obstructive pulmonary disease 4 (7.4) 3 (4.8) NS Congestive heart failure 3 (5.5) 5 (8.0) NS Renal failure 1.09 2 (32.2) NS Arrial fibrillation type 7 26 (4.9) NS Arrial fibrillation persistem 32 (29.3) 36 (58.1) NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS New York Heart Association Functional Class 3 [2-3] NS NS New York Heart Association Functional Class 2 (40.7)
Construction Construction<
Hypertension 20 (37.1) 21 (33.9) NS Diabetes 14 (25.9) 15 (24.1) NS Cerebrovascular disease 6 (11.1) 6 (9.6) NS Consci obstructive pulmonary disease 4 (7.4) 3 (4.8) NS Consci obstructive pulmonary disease 4 (7.4) 3 (4.8) NS Consci obstructive pulmonary disease 1 (19) 2 (3.2) NS Arrial fibrillation type 1 (19) 2 (3.2) NS Arrial fibrillation duration before surgery (months) 33 (27-44] 28 [21-37] NS New York Heart Association Functional Class 3 [27-3] 3 [2.7-41] NS Ne York Heart Association Functional Class 3 [27-2] 1 (3.9) NS II 10 (22.2) 1 (3.9) NS II 10 (22.2) 1 (3.9) NS Mitral valve pathology 1 1 (22.2) 1 (3.9) NS Mitral valve pathology 1 1 (19) 1 (17.7) NS Mitral valve pathology 4 (7.4) 5 (8.1) 1
Injectation In (250) In (241) No Dabetes 14 (253) 16 (241) No Cerebrovascular disease 6 (11.1) 6 (9.6) NS Concoin constructive pulmonary disease 4 (7.4) 3 (4.8) NS Congestive heart failure 3 (5.5) 5 (8.0) NS Renal failure 1 (19) 2 (3.2) NS Arrial fibrillation type
Dataset 11 (20.7) 15 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 16 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7) 17 (21.7)
Chronic obtain disease 0 (111) 0 (30) 10 Chronic obtain disease 1 (12) 1 (30) NS Congestive heart failure 3 (5.5) 5 (8.0) NS Renal failure 1 (19) 2 (3.2) NS Atrial fibrillation type 2 2 (40.7) 26 (41.9) 26 (41.9) Atrial fibrillation duration before surgery (months) 33 [27-44] 28 [21-37] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS II 12 (22.2) 21 (33.9) NS III 30 (55.6) 27 (43.6) V NV New York Heart Association Functional Class 3 [4-6-2] 0 (50-70] NS III 10 (55.6) 12 (22.2) 14 (22.5) V Vir 12 (22.2) 14 (22.5) V NS Degenerative 26 (48.2) 3 (50.1) S S Degenerative 26 (48.2) 3 (50.1) S NS Insufficiency 4 (74) 2 (32.) NS NS
Curronic Districture planifolitary useage 4 (74) 5 (43) NS Congestive heart failure 1 (19) 2 (32) NS Renal failure 1 (19) 2 (32) NS Arrial fibrillation type 2 2 (40.7) 26 (41.9) NS Long-standing persistent 22 (40.7) 28 [21-37] NS Arrial fibrillation duration before surgery (months) 31 [27-44] 28 [21-37] NS New York Heart Association Functional Class 31 [27-44] 28 [21-37] NS New York Heart Association Functional Class 31 [27-41] 32 [27-41] 32 [27-41] NS Il 12 (22.2) 21 (33.9) I II NS Il 12 (22.2) 14 (22.5) I II II NS Degenerative 53 [40-62] 60 [50-7.0] NS II InstrictureIII NS Degenerative 26 (48.2) 31 (50.1) II III III III III III III III IIII IIII IIII
Congestive iteat rating 5 (3.5) 5 (8.0) NS Renal failure 1 (1.9) 2 (3.2) NS Atrial fibrillation type 2 2 (3.2) NS Long-standing persistent 22 (40.7) 26 (41.9) NS Atrial fibrillation duration before surgery (months) 33 [27-44] 28 [21-37] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS II 12 (22.2) 21 (33.9) NS III 30 (55.6) 27 (43.6) NS New York Heart Association Functional Class 3 [2-3] 0.6 [50-7.0] NS Mitral valve pathology 12 (22.2) 14 (22.5) NS EuroScore 5.0 [60.7.0] 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) NS Ischemic 1 (1.9) 1 (4 (25.9) 14 (22.5) Functional 0 (7.0) 13 (50.1) NS Ischemic 1 (1.9) 2 (3.2) NS Instructional 0 (7.9) 1 (25.8)
Relation lation I (1.5) 2 (3.2) NS Arrial fibrillation type NS Persistent 22 (59.3) 36 (58.1) NS Long-standing persistent 22 (40.7) 26 (41.9) Atrial fibrillation duration before surgery (months) 33 [27-44] 28 [21-37] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS II 12 (22.2) 21 (33.9) NS IW 12 (22.2) 14 (22.5) EuroScore 51 [40-62] 6.0 [50-70] NS Degenerative 52 (48.2) 31 (50.1) Degenerative 26 (48.2) 31 (50.1) NS Degenerative 11 (1.9) 1 (1.7) NS Other 1 (1.9) 2 (3.2) NS Install Evicon 1 1.19 2 (3.2) NS <
Artial influiton type Persisent 22 (59.3) 36 (58.1) NS Long-standing persistent 22 (40.7) 26 (41.9) NS Atrial fibrillation duration before surgery (months) 33 [27-44] 28 [21-37] NS New York Heart Association Functional Class 12 (22.2) 21 (33.9) NS II 12 (22.2) 14 (22.5) NS Notical value pathology 12 (22.2) 14 (22.5) NS Nitral value pathology 26 (48.2) 31 (50.1) NS Degenerative 26 (48.2) 31 (50.1) NS Noter 14 (25.9) 14 (22.5) NS Other 14 (25.9) 14 (22.5) NS Insufficiency 40 (74) 5 (8.1) NS Noter 10 (1.9) 2 (32.0) NS Insufficiency 40 (90.7) 58 (93.6) NS Insufficiency 40 (74.4) 2 (32.0) NS Insufficiency 16 (29.6) 18 (29.0) NS Insufficiency 40 (74.4)
Persistent 32 (29.3) 36 (28.1) N Long-standing persistent 22 (40.7) 26 (41.9) N Artial fibrillation ductation before surgery (months) 33 [27-4] 28 [21-37] NS New York Heart Association Functional Class 3 [2-3] 3 [2-3] NS II 12 (22.2) 21 (33.9) NS III 30 (55.6) 27 (43.6) NS EuroScore 53 [40-62] 60 [50-7.0] NS Mitral valve pathology NS NS NS NS Begenerative 53 [40-62] 60 [50-7.0] NS NS Degenerative 53 [40-62] 60 [50-7.0] NS NS Degenerative 14 (25.9) 11 (17.7) NS Degenerative 14 (25.9) 14 (22.5) NS Other 11 (19.7) 16 (3.6) NS Insufficiency 49 (90.7) 58 (93.6) NS Insufficiency 49 (90.7) 58 (93.6) NS Insufficiency 16 (29.6) 18 (20
Long-standing persistent 22 (40.7) 26 (41.9) Atrial fibrillation duration before surgery (months) 33 [27-44] 28 [21-37] NS New York Heart Association Functional Class 3 [2-3] 1 NS II 12 (22.2) 21 (33.9) NS II 30 (55.6) 27 (43.6) NS NV 12 (22.2) 14 (22.5) NS Burdary pathology 11 (17.7) NS Persone 9 (16.7) 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) S Ischemic 14 (22.5) 14 (22.5) 14 (22.5) Functional 4 (7.4) 5 (8.1) 1 Other 1 (1.9) 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) 1 Insufficiency 49 (90.7) 58 (93.6) NS Insufficiency 49 (90.7) 58 (93.6) NS Insufficiency 49 (90.7) 58 (93.6) NS Insufficiency 49 (90.7) 18 (20.0)
Atrial ibnilation duration before surgery (months) 33 [2/-3] 28 [21-3] NS New York Heart Association Functional Class 31 (22.2) 21 (33.9) II 12 (22.2) 21 (33.9) II 12 (22.2) 14 (22.5) EuroScore 53 [40-62] 6.0 [50-7.0] NS Mitral valve pathology 11 (17.7) NS Rheumatic 9 (16.7) 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) NS Ischemic 14 (25.9) 14 (22.5) NS Functional 4 (7.4) 5 (8.1) Other Other 1 (1.9) 1 (1.6) NS Mitral lesion 4 (7.4) 5 (8.9.6) NS Insufficiency 49 (90.7) 58 (93.6) NS Mixed 4 (7.4) 2 (3.2) NS Coronary attery disease 16 (29.6) 16 (25.8) NS Artict valve disease 7 (12.9) 12 (19.3) NS Ich attraits (min) 52.3 ± 9.0 55.1 ± 11.5 NS Left attraits (ate (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left variatize (mm) 52.3 ± 9.0 55.1 ± 11.5 NS End atsotic diameter (mm) 52.3 ± 3.3 58
New York Heart Association Functional Class 3 [2-3] 3 [2-3] Ns II 12 (22.2) 21 (33.9) 1 IV 12 (22.2) 14 (22.5) Ns EuroScore 53 [4.0-6.2] 6.0 [5.0-7.0] NS Mitral valve pathology 11 (17.7) NS Degenerative 66 (48.2) 31 (50.1) 1 Ischemic 14 (25.9) 14 (22.5) 1 Functional 68 (48.2) 31 (50.1) 1 Other 1 (1.9) 1 (16.0) 1 1 Mitral lesion 1 (1.9) 1 (1.6) 1 1 1 1 Mixed 9 (90.7) 58 (93.6) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
II 12 (22) 21 (33) III 30 (55.6) 27 (43.6) IV 12 (22.2) 14 (22.5) EuroScore 53 [4.0-6.2] 60 [5.0-7.0] NS Mitral valve pathology 11 (17.7) NS Degenerative 9 (16.7) 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) 1 Ischemic 14 (25.9) 14 (22.5) 14 Other 1 (1.9) 1 (1.6) 1 Mitral lesion 11 (1.9) 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) 1 Mixed 47.4) 2 (3.2) NS Insufficiency 16 (29.6) 16 (25.8) NS Notic valve disease 7 (12.9) 12 (19.3) NS Coronary artery disease 16 (29.6) 18 (29.0) NS Inf. valve disease 16 (29.6) 18 (29.0) NS Left artial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left vertricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS Left vertricular ejection fraction (%) 52.3 ± 9.0 55.1 ± 1.5 NS Left vertricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9
III 30 (5 6.) 27 (4 3.6) IV 12 (2 2.2) 14 (2 2.5) EuroScore 6.0 [5.0-7.0] NS Mitral valve pathology 5.3 [4.0-6.2] 6.0 [5.0-7.0] NS Mitral valve pathology 9 (16.7) 11 (17.7) NS Degenerative 26 (4 8.2) 31 (50.1) NS Ischemic 14 (2 5.9) 14 (2 2.5) NS Functional 4 (7.4) 5 (8.1) Other Other 10.9) 11.6) NS Instrificiency 9 (90.7) 58 (93.6) NS Instrificiency 9 (90.7) 58 (93.6) NS Mixed 4 (7.4) 2 (3.2) NS Instrificiency 4 (7.4) 2 (3.2) NS Instrificiency 4 (7.4) 2 (3.2) NS Instrificiency 16 (29.6) 18 (29.0) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Infcuspid valve disease 5 (3 ± 1.15. NS End systolic diameter (
N 12 (22) 14 (22.5) EuroScore 53 (40-62) 60 [50-7.0] NS Mitral valve pathology 9 11 (17.7) NS Degenerative 9 (16.7) 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) NS Ischemic 14 (25.9) 14 (22.5) 14 (22.5) Functional 0 (15.0) 12 (25.9) 14 (22.5) Other 1 (19.0) 2 (32.0) NS Instificiency 9 (90.7) 58 (93.6) NS Instificiency 9 (90.7) 58 (93.6) NS Other 1 (19.9) 2 (3.2) NS Instificiency 49 (90.7) 58 (93.6) NS Instificiency 49 (90.7) 58 (93.6) NS Ortonary attery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Infitial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm)
Euroscore 5.3 [40–6.2] 6.0 [5.0–7.0] NS Mitral valve pathology
Miral valve pathology 9 (16.7) 11 (17.7) NS Rheumatic 9 (16.2) 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) 14 (22.5) Ischemic 14 (25.9) 14 (22.5) 14 (22.5) Functional 4 (7.4) 5 (8.1) 1 Other 1 (1.9) 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) 1 Mixed 4 (7.4) 2 (3.2) NS Coronary artery disease 4 (7.4) 2 (3.2) NS Mixed 4 (7.4) 2 (3.2) NS Coronary artery disease 16 (29.6) 16 (25.8) NS Acritic valve disease 16 (29.6) 18 (29.0) NS Infection (%) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 55.5 ± 11.9 NS End diastoli ciameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery Keplar 42 (77.8) 46 (74.2) NS Mitral valve surgery Keplar 42 (77.8) 46 (74.2) NS
Rheumatic 9 (16.7) 11 (17.7) NS Degenerative 26 (48.2) 31 (50.1) 1 Ischemic 14 (25.9) 14 (22.5) 1 Functional 4 (7.4) 5 (8.1) 1 Other 1 (1.9) 1 (1.6) NS Mitral lesion 1 1.9 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) NS Mixed 4 (7.4) 2 (3.2) NS Actric valver disease 16 (29.6) 16 (25.8) NS Actric valver disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left atrial size (mm) 56.0 ± 11.6 58.5 ± 11.9 NS Left atrial size (mm) 51.3 ± 4.3 30.5 ± 2.2 NS End systolic diameter (mm) 51.3 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery It Keplar Keplar NS End systolic diameter (mm) 51.3 ± 4.3 51.8 ± 4.0 NS
Degenerative 26 (48.2) 31 (50.1) Ischemic 14 (25.9) 14 (22.5) Functional 6 (8.1) 5 (8.1) Other 1 (1.9) 1 (1.6) Mitral lesion 2 (3.2) NS Insufficiency 4 (7.4) 2 (3.2) NS Insufficiency 4 (7.4) 2 (3.2) NS Insufficiency 4 (7.4) 2 (3.2) NS Coronary artery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End diastolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery NS 51.8 ± 4.0 NS Mitral valve surgery 42 (77.8) 46 (74.2) NS Replacement NS
Ischemic 14 (25.9) 14 (22.5) Functional 4 (7.4) 5 (8.1) Other 1 (1.9) 1 (1.6) Mitral lesion 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) 1 Mixed 2 (3.2) NS Aoronary artery disease 16 (29.6) 58 (93.6) NS Aoric valve disease 7 (12.9) 12 (19.3) NS Aric valve disease 16 (29.6) 18 (29.0) NS Left artial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End diastolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery 1 14 (29.78) NS NS Mitral valve surgery 42 (77.8) 46 (74.2) MS Replacement 11 (17.7) 11 (17.7) 11 (17.7)
Functional Other 4 (7.4) 5 (8.1) Other 1 (1.9) 11.6) Mitral lesion 1 1.9) 1.6) Stenosis 1 (1.9) 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) 1 Mixed 4 (7.4) 2 (3.2) NS Coronary artery disease 16 (29.6) 16 (25.8) NS Artic valve disease 7 (12.9) 12 (19.3) NS Tricuspid valve disease 6 (29.6) 18 (29.0) NS Left artial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left vertricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End diastolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery NS 51.8 ± 4.0 NS Mitral valve surgery Kepair 42 (77.8) 46 (74.2) NS Replacement NS 51.48 11 (17.7) NS
Other 1 (1.9) 1 (1.9) Mitral lesion - Stenosis 1 (1.9) 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) - Mixed 4 (7.4) 2 (3.2) S Coronary artery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Tricuspid valve disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery
Mitral lesion X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 X 1 <
Stenosis 1 (1.9) 2 (3.2) NS Insufficiency 49 (90.7) 58 (93.6) 78 Mixed 4 (7.4) 2 (3.2) 78 Coronary artery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery T T NS Mitral valve surgery 42 (77.8) 46 (74.2) NS Replacement Bioprosthesis 8 (14.8) 11 (17.7)
Insufficiency 49 (90.7) 58 (93.6) Mixed 4 (7.4) 2 (3.2) Coronary artery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Tricuspid valve disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery NS Repair 42 (77.8) 46 (74.2) NS Replacement NS Bioprosthesis 8 (14.8) 11 (17.7)
Mixed 4 (7.4) 2 (3.2) Coronary artery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Tricuspid valve disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery Titrave surgery NS NS Repair 42 (77.8) 46 (74.2) NS Replacement 8 (14.8) 11 (17.7) NS
Coronary artery disease 16 (29.6) 16 (25.8) NS Aortic valve disease 7 (12.9) 12 (19.3) NS Tricuspid valve disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery 11 11 NS Repair 42 (77.8) 46 (74.2) NS Replacement 8 (14.8) 11 (17.7) 11
Aortic valve disease 7 (12.9) 12 (19.3) NS Tricuspid valve disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS Mitral valve surgery 7.23 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery 42 (77.8) 46 (74.2) NS Replacement 8 (14.8) 11 (17.7) 11 (17.7)
Instruction function 112 (130) 113 (140) Tricuspid valve disease 16 (29.6) 18 (29.0) NS Left atrial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS End diastolic diameter (mm) 52.3 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery Image: Comparison of the surgery NS Repair 42 (77.8) 46 (74.2) NS Replacement Image: Comparison of the surgery Image: Comparison of the surgery NS
Interpret value 10 (2.50) 10 (2.50) 10 (2.50) 15 (2.50) Left attial size (mm) 52.3 ± 9.0 55.1 ± 11.5 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS End diastolic diameter (mm) 52.3 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery Repair 42 (77.8) 46 (74.2) NS Repair 8 (14.8) 11 (17.7) 11 (17.7)
Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS Left ventricular ejection fraction (%) 56.0 ± 11.6 58.5 ± 11.9 NS End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS End diastolic diameter (mm) 52.3 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery Repair 42 (77.8) 46 (74.2) NS Replacement 11 (17.7) 11 (17.7) 11 (17.7)
End systolic diameter (mm) 31.4 ± 3.3 30.5 ± 2.2 NS End distolic diameter (mm) 52.3 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery 42 (77.8) 46 (74.2) NS Replacement 8 (14.8) 11 (17.7) 11 (17.7)
End diastolic diameter (mm) 51.4 ± 5.5 50.5 ± 2.2 NS End diastolic diameter (mm) 52.3 ± 4.3 51.8 ± 4.0 NS Mitral valve surgery Repair 42 (77.8) 46 (74.2) NS Replacement Bioprosthesis 8 (14.8) 11 (17.7)
Mitral valves surgery 32.5 ± 4.5 31.8 ± 4.0 NS Mitral valve surgery 42 (77.8) 46 (74.2) NS Replacement 8 (14.8) 11 (17.7)
Repair42 (77.8)46 (74.2)NSReplacement8 (14.8)11 (17.7)
Replacement 42 (77.8) 46 (74.2) NS Bioprosthesis 8 (14.8) 11 (17.7)
Bioprosthesis 8 (14.8) 11 (17.7)
Bioprostnesis 8 (14.8) 11 (17.7)
$\frac{1}{1000} \frac{1}{1000} \frac{1}{1000} \frac{1}{10000} \frac{1}{10000000000000000000000000000000000$
Coronary artery bypass gratting 16 (29.6) 14 (22.5) NS
Anastomoses (n) 2.0 [2–3] 2.5 [2–3]
Aortic valve replacement
Bioprosthesis 6 (11.1) 6 (9.6) NS
Mechanical 1 (1.9) 4 (6.4)
Tricuspid valve repair 14 (25.9) 16 (25.8) NS
Right atrial lesions 3 (5.5) –
Left atrial appendage exclusion/ligation 52 (96.2) –
Ganglia ablation 11 (20.4) –
Cardiopulmonary bypass time (min) 170 ± 40 160 ± 34 NS
Aortic cross clamp time (min). 144 ± 29 129 ± 20 NS

Values are expressed as mean ± standard deviation (normally distributed data), median [Interquartile range] (non-normally distributed data) or n (%). Abbreviations: NS: not significant.

Download English Version:

https://daneshyari.com/en/article/5971153

Download Persian Version:

https://daneshyari.com/article/5971153

Daneshyari.com